NEW YORK, Jan. 14, 2015 /PRNewswire/ -- The HIV Partnering 2009-2014 provides understanding and access to the HIV partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of HIV partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors HIV technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 260 links to online copies of actual HIV deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of HIV partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in HIV partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading HIV deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of HIV partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of HIV technologies and products.
Report scope
HIV Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to HIV trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
Trends in HIV dealmaking in the biopharma industry since 2009
Access to summary headline, upfront, milestone and royalty data
The leading HIV deals by value since 2009
In HIV Partnering 2009-2014, the available deals are listed by:
Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
HIV Partnering 2009-2014 provides the reader with the following key benefits:
In-depth understanding of HIV deal trends since 2009
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 260 actual HIV deals entered into by the world's biopharma companies since 2009
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in HIV partnering
2.1. Introduction
2.2. HIV partnering over the years
2.3. Bigpharma HIV dealmaking activity
2.4. HIV partnering by deal type
2.5. HIV partnering industry sector
2.6. HIV partnering by stage of development
2.7. HIV partnering by technology type
2.8. Disclosed financial deal terms for HIV partnering
2.8.1 HIV headline values
2.8.2 HIV upfront payments
2.8.3 HIV milestone payments
2.8.4 HIV royalty rates
Chapter 3 – Leading HIV deals
3.1. Introduction
3.2. Top HIV deals by value
3.3. Top HIV deals involving bigpharma
Chapter 4 – Dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendices
Appendix 1 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Table of figures
Figure 1: HIV partnering since 2009
Figure 2: Bigpharma – top 50 – HIV deals 2009 to 2011
Figure 3: Bigpharma HIV deal frequency – 2009 to 2011
Figure 4: HIV partnering by deal type since 2009
Figure 5: HIV partnering by industry sector since 2009
Figure 6: HIV partnering by stage of development since 2009
Figure 7: HIV partnering by technology type since 2009
Figure 8: HIV deals with a headline value
Figure 9: HIV deals with upfront payment values
Figure 10: HIV deals with milestone payments
Figure 11: HIV deals with royalty rates, %
Figure 12: Top HIV deals by value since 2009
Figure 13: Top HIV deals signed by bigpharma value since 2009
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions
$1,695: single-user
$2,595: multi-user
$5,095: single site license
$8,475: global site license
An annual subscription to quarterly updates can be purchased for a small additional fee; ensuring you are kept up-to-date with the very latest HIV partnering deals. Quarterly updates available from $847.50.
A full explanation of license type definitions can be found here.
An additional $500 per copy will be added for full print and CD-ROM requests.
Read the full report: http://www.reportlinker.com/p0936034-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article